Pharmac to fund injectable letermovir to prevent cytomegalovirus infection

Imported from official source

Announcement

Safety Classified by Officially

Pharmac will fund the injectable form of letermovir (marketed as Prevymis) from 1 December to prevent cytomegalovirus (CMV) infection in people who have had an allogenic haematopoietic stem cell transplant (allo-HSCT), or who are severely immunosuppressed.

Pharmac’s  Manager Pharmaceutical Funding Michaela Lion, says the decision to fund letermovir in injectable form follows Pharmac’s decision on 1 May this year to fund the treatment in tablet form.

Clinicians advised Pharmac that relying solely on the tablet formulation could create challenges with accurate dosing for some patients and may not be suitable for patients who have difficulty swallowing tablets.

Letermovir in tablet form will remain funded and available for patients alongside the injectable form and will be available for use in hospitals and community pharmacies.

Lion says CMV is a common, usually harmless virus most people are exposed to in childhood.

“CMV stays in the body for life without causing problems for most people but can cause serious illness in people whose immune systems are not working properly, particularly those who have had an allo-HSCT.”

She says letermovir works by preventing CMV from becoming active, and it has been tremendous to hear pharmacists and clinicians report no cases of CMV reactivation or infection in this group of patients since letermovir was funded earlier this year.

Preventing CMV can help reduce serious illness and complications, avoid long hospital stays and intensive treatment, and support people to recover at home sooner and spend less time away from whānau, Lion says.
It is estimated up to 56 people will benefit from using the injectable form of letermovir in the first 12 months.

From 1 December 2026 the injectable form of letermovir (brand name Prevymis) will be funded for:

  • people who have had an allogenic haematopoietic stem cell transplant (allo-HSCT), and
  • a small number of other people with severe immunosuppression who cannot use other funded antiviral medicines.
  • This is an extract. The publication continues at the source.

    © Pharmac, licensed under CC BY 4.0. Licence

    Read the original at the source: https://www.pharmac.govt.nz/news-and-resources/news/2026-11-pharmac-to-fund-injectable-letermovir-to-prevent-cytomegalovirus-infection

    Officially imported this from Pharmac’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.

    Provenance

    Organization
    Pharmac — imported from official source
    Official source
    https://www.pharmac.govt.nz/news-and-resources/news/rss RSS
    Imported
    November 10, 2026 01:31
    Versions
    1 recorded
    Identity
    https://www.pharmac.govt.nz/news-and-resources/news/2026-11-pharmac-to-fund-injectable-...

    Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.